WHO intensifies Ebola-curbing efforts through drug trial and diagnostic rollout
The World Health Organization (WHO) has taken fresh steps to curb the rising Ebola epidemic in central Africa caused by…
03 Jul 2026
US-UK pharma trade deal paints a costly economic picture for NHS
The UK-US pharmaceuticals deal could cost the National Health Service (NHS) around £45bn ($60bn) within a decade and divert resources away from essential services, an analysis has suggested. The UK…
03 Jul 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions. The project will involve…
03 Jul 2026
European Commission approves Novartis’ Itvisma to treat SMA
The European Commission has granted approval for Novartis’ Itvisma (onasemnogene abeparvovec) as a treatment for children two years and older, teenagers and adults who have 5q spinal muscular atrophy (SMA)…
02 Jul 2026
Ipsen bolsters rare disease pipeline in €700m Memo takeover
Ipsen has outlaid €700m ($798.4m) to acquire rare disease specialist Memo Therapeutics – enriching its pipeline with a mid-stage clinical asset. As part of the takeover, the Paris, France-based pharma…
02 Jul 2026
FDA widens Vertex’s Casgevy use for paediatric patients
The US Food and Drug Administration (FDA) has approved expanded use of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in children with one of two types of inherited blood disorders, marking the…
02 Jul 2026
Insilico Medicine, Takeda partner on AI-driven drug discovery
Insilico Medicine has entered into a strategic collaboration agreement with Takeda to deploy its AI-based Pharma.AI platform in the discovery and development of drug candidates. Under the agreement, Insilico will…